These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28049945)

  • 1. Inflammatory Effects of Nitrogen-Containing Bisphosphonates (N-BPs): Modulation by Non-N-BPs.
    Shima K; Tsuchiya M; Oizumi T; Takano-Yamamoto T; Sugawara S; Endo Y
    Biol Pharm Bull; 2017; 40(1):25-33. PubMed ID: 28049945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphonocarboxylates Can Protect Mice against the Inflammatory and Necrotic Side Effects of Nitrogen-Containing Bisphosphonates by Inhibiting Their Entry into Cells via Phosphate Transporters.
    Kiyama T; Tsuchiya M; Okada S; Oizumi T; Yamaguchi K; Sasaki K; Sugawara S; Endo Y
    Biol Pharm Bull; 2016; 39(5):712-20. PubMed ID: 27150143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
    Okada S; Kiyama T; Sato E; Tanaka Y; Oizumi T; Kuroishi T; Takahashi T; Sasaki K; Sugawara S; Endo Y
    Tohoku J Exp Med; 2013 Oct; 231(2):145-58. PubMed ID: 24140868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bisphosphonates Clodronate and Etidronate Exert Analgesic Effects by Acting on Glutamate- and/or ATP-Related Pain Transmission Pathways.
    Shima K; Nemoto W; Tsuchiya M; Tan-No K; Takano-Yamamoto T; Sugawara S; Endo Y
    Biol Pharm Bull; 2016; 39(5):770-7. PubMed ID: 27150146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
    Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T
    Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
    Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
    Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory and necrotic effects of minodronate, a nitrogen-containing bisphosphonate, in mice.
    Kiyama T; Okada S; Tanaka Y; Kim S; Bando K; Hasegawa M; Yamaguchi K; Takano-Yamamoto T; Sasaki K; Sugawara S; Endo Y
    Tohoku J Exp Med; 2013 Jul; 230(3):141-9. PubMed ID: 23822921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive effects of N-bisphosphonate in osteoblastic cells mitigated by non-N-bisphosphonate but not by sodium-dependent phosphate cotransporter inhibitor.
    Baba TT; Miyazaki T; Ohara-Nemoto Y; Nemoto TK
    Cell Biochem Funct; 2019 Aug; 37(6):400-407. PubMed ID: 31328801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of Lipopolysaccharide-Induced Production of IL-1α and IL-1β in Mice Given Intravenous Zoledronate (a Nitrogen-Containing Bisphosphonate) and Its Prevention by Clodronate (a Non-nitrogen-containing Bisphosphonate).
    Suzuki H; Bando K; Tada H; Kiyama T; Oizumi T; Funayama H; Sugawara S; Takahashi T; Endo Y
    Biol Pharm Bull; 2019; 42(2):164-172. PubMed ID: 30713248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Strategy against the Osteonecrosis of the Jaw Associated with Nitrogen-Containing Bisphosphonates (N-BPs): Attempts to Replace N-BPs with the Non-N-BP Etidronate.
    Oizumi T; Yamaguchi K; Sato K; Takahashi M; Yoshimura G; Otsuru H; Tsuchiya M; Hagiwara Y; Itoi E; Sugawara S; Takahashi T; Endo Y
    Biol Pharm Bull; 2016; 39(9):1549-54. PubMed ID: 27582334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate.
    Funayama H; Ohsako M; Monma Y; Mayanagi H; Sugawara S; Endo Y
    Calcif Tissue Int; 2005 Jun; 76(6):448-57. PubMed ID: 15895282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone.
    Kim S; Seiryu M; Okada S; Kuroishi T; Takano-Yamamoto T; Sugawara S; Endo Y
    Eur J Pharmacol; 2013 Jan; 699(1-3):14-22. PubMed ID: 23201069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate.
    Oizumi T; Yamaguchi K; Funayama H; Kuroishi T; Kawamura H; Sugawara S; Endo Y
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):384-92. PubMed ID: 19413658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
    Oizumi T; Funayama H; Yamaguchi K; Yokoyama M; Takahashi H; Yamamoto M; Kuroishi T; Kumamoto H; Sasaki K; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 May; 68(5):1043-54. PubMed ID: 20156665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiology of the aging bone and mechanisms of action of bisphosphonates.
    Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
    Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
    Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
    Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase.
    Ohno K; Mori K; Orita M; Takeuchi M
    Curr Med Chem; 2011; 18(2):220-33. PubMed ID: 21110804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitrogen-containing bisphosphonates and lipopolysaccharide mutually augment inflammation via adenosine triphosphate (ATP)-mediated and interleukin 1β (IL-1β)-mediated production of neutrophil extracellular traps (NETs).
    Bando K; Kuroishi T; Tada H; Oizumi T; Tanaka Y; Takahashi T; Mizoguchi I; Sugawara S; Endo Y
    J Bone Miner Res; 2021 Sep; 36(9):1866-1878. PubMed ID: 34075628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development.
    Soares AP; do Espírito Santo RF; Line SR; Pinto Md; Santos Pde M; Toralles MB; do Espírito Santo AR
    Environ Toxicol Pharmacol; 2016 Mar; 42():212-7. PubMed ID: 26895384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.